Lessons Learned from Transgenic Mouse Models for the Therapeutic Use of Drp1 Inhibitors
- *Corresponding Author:
- Björn Oettinghaus
Division of Neuropathology
Institute of Pathology
University Hospital Basel
Schönbeinstrasse 40, CH-4031 Basel, Switzerland
Tel: +41 61 265 27 76
E-mail: [email protected]
Received date: March 22, 2016; Accepted date: April 11, 2016; Published date: April 13, 2016
Citation: Maria L, Björn O (2016) Lessons Learned from Transgenic Mouse Models for the Therapeutic Use of Drp1 Inhibitors. Single Cell Biol 5:135. doi:10.4172/2168-9431.1000135
Copyright: © 2016 Maria L, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Pharmacological inhibition of dynamin-related protein 1 (Drp1) the main mammalian promoter of mitochondrial fission - has emerged as a promising therapeutic target for the treatment of neuronal injuries. Genetic studies, however, have revealed that inhibiting Drp1 during development leads to defects especially in neuronal differentiation. Bypassing this neurodevelopmental impairment, a number of recent studies have genetically ablated Drp1 in different adult neuronal subpopulations. This has led to new insights into the importance of mitochondrial fission in differentiated neurons and has highlighted potentially severe side effects of this new therapeutic strategy.